Volociximab
Jump to navigation
Jump to search
Template:Short description Template:Drugbox
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]
It is thought to reduce metastases. Early results show potential in renal cell cancers.Script error: No such module "Unsubst".
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "Citation/CS1".
Script error: No such module "Check for unknown parameters".
External links
Template:Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems